Arch Biopartners Expands Phase II Cardiac Surgery-Associated AKI Trial to Include Royal Columbian Hospital in British Columbia

Executive Summary

• The Royal Columbian Hospital received REB approval to join Arch’s Phase II LSALT peptide trial for cardiac‑surgery associated acute kidney injury, becoming the eighth global site and fourth in Canada.
• TSX Venture Exchange gave final approval for Arch’s acquisition of Lipdro Therapeutics Inc., issuing 250,000 Arch common shares plus a royalty on future CKD drug sales.
• The Board granted 750,000 stock options to directors and officers at $1.70 per share, exercisable over ten years.

Key Details

• Clinical Trial Expansion
• REB approval obtained for Royal Columbian Hospital (RCH) in New Westminster, BC.
• RCH will complete operational approvals, training, and site initiation before patient enrollment.
• RCH is the eighth global site and expected to be the fourth Canadian recruiting location.

• Other active sites: Toronto General Hospital (UHN), University of Calgary Cumming School of Medicine; St. Michael’s Hospital awaiting Clinical Trials Ontario authorization.

• Acquisition of Lipdro Therapeutics

• TSX Venture Exchange approved Arch’s acquisition of Lipdro Therapeutics Inc.
• Consideration: 250,000 Arch common shares issued to Lipdro shareholders.

• Additional consideration: royalty on future net sales of CKD drug candidates derived from the newly acquired CKD platform targeting IL‑32.

• Equity Compensation

• Board approved issuance of 750,000 stock options to directors and officers under Arch’s stock option plan.
• Exercise price: $1.70 per share.
• Term: ten years, effective November 4 2025, subject to regulatory approvals.

• Purpose: remuneration for service periods ending April 1 2025 and April 1 2026.

• Company Context

• Arch Biopartners focuses on therapies for acute and chronic kidney disease.
• Pipeline highlights: LSALT peptide (Phase II CS‑AKI), Cilastatin (Phase II toxin‑induced AKI), CKD therapeutics (preclinical).

Notable Quotes

No direct quotes were provided in the release.